Trade Amarin Corporation plc - AMRN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.2304
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 11.835
• Open: 11.845
• 1-Year Change: -38.43%
• Day's Range: 11.845 - 12.0148

Trade Amarin Corporation plc - AMRN

Amarin Corporation (AMRN) is a clinical-stage biopharmaceutical company focused on the commercialisation and improvement of therapeutics to cure and deal with cardiovascular diseases. 

Established in 1989, Amarin is headquartered in Dublin, Ireland, and operates in several European countries, the United States, Canada, Lebanon and the United Arab Emirates. 

The company’s lead commercial product VASCEPA (icosapent ethyl) is a prescription-only omega-3 fatty acid product. Taken as an adjunct to diet, it reduces triglyceride levels in adult patients suffering from severe hypertriglyceridemia. The drug helps to address cardiovascular risk for millions of patients.

VASCEPA was launched in the United States in 2013, but gained wider recognition in 2019  as the US Food and Drug Administration (FDA) approved Amarin for a broader indication for cardiovascular risk reduction in studied high-risk patients. It has also got approval from the European Commission to reduce the risks for cardiac patients.

Amarin still prices VASCEPA at a considerably lower level than other new drugs of its category. 

Formerly known as Ethical Holdings, the company changed its name to Amarin Corporation in 1999. The company went public in July 2019. It trades on the Nasdaq under the ticker ‘AMRN’.